Nuwellis faced headwinds in 2025 with revenue declining 5.38% to $8.27M and losses expanding to $17.52M. The company appointed Mike McCormick as CEO effective June 30, 2026, with John Erb transitioning to Chairman. Nuwellis announced a public offering of 20M shares for approximately $6M in gross proceeds in June 2026, indicating capital-raising efforts to support operations and growth initiatives.
Cyborg Score Rationale
Nuwellis operates in a specialized medical device niche with FDA-cleared technology, but faces significant revenue contraction, mounting losses, and dilutive financing. Recent leadership transition and international exit signal strategic repositioning, but execution risk remains high for a micro-cap company.
Top Insights
Nuwellis announced plans to exit international operations in August 2025 to accelerate U.S. revenue growth and strategic focus
The company received FDA 510(k) clearance for a new dual lumen extended length catheter in August 2025
Nuwellis received a $3M NIH grant in September 2025 to accelerate its Vivian pediatric platform
Company is pursuing expanded clinical collaborations, including an integration with a South Carolina healthcare system for pediatric applications
Named Competitors
Fresenius Dialysis — Global dialysis and renal care provider
Baxter IV Solutions — Fluid management and IV therapy solutions
Outset Dialysis — Portable dialysis and fluid management systems
Recent Developments
(June 2026) CEO transition: Mike McCormick appointed CEO effective June 30, 2026
(June 2026) Public offering of 20M shares with warrants for approximately $6M gross proceeds
(August 2025) Announced exit from international operations to focus on U.S. market growth
(September 2025) Received $3M NIH grant for Vivian pediatric platform development
Open the full interactive Nuwellis, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.